<!DOCTYPE html>
<html>
    <head>
        <title>Description | iGem Winter Project</title>
        <<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no">
        <link rel="icon" type="image/png" href="../static/img/favicon.ico">
        <script type="module" src="https://unpkg.com/ionicons@5.5.2/dist/ionicons/ionicons.esm.js"></script>
        <script nomodule src="https://unpkg.com/ionicons@5.5.2/dist/ionicons/ionicons.js"></script>
        <link rel="stylesheet" href="../static/css/basic.css">
        <link rel="stylesheet" href="../static/css/load.css">
        <link rel="stylesheet" href="../static/css/pages.css">
        <link rel="stylesheet" href="../static/css/components.css">
        <link rel="stylesheet" href="../static/css/pdbviewer.css">
        <script src="https://unpkg.com/ngl@2.0.0-dev.37/dist/ngl.js"></script>
    </head>
    <body>
        <!-- scroll progress bar -->
        <div class="scroll-progress"></div>
        
        <!-- Loading cast -->
        <div class="loading-container">
            <div class="loading-spinner-image">
                <img src="../static/img/loading.svg" alt="Loading...">
            </div>
            <div class="loading-text">Loading...</div>
        </div>

        <!-- Topbar -->
        <div class="top_bar">
            <div class="menu_btn">
                <ion-icon name="menu-outline"></ion-icon>
            </div>
            <div class="logo_wrap">
                <a href="../index.html"><img id="team_logo" src="../static/img/logo-apart-text.svg" alt=""></a>
            </div>
            <div class="menu_wrap">
                <div id="project" class="menu_item menu_item_cur">
                    <div class="title">Project<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./description.html">Description</a></li>
                        <li><a href="./design.html">Design</a></li>
                        <li><a href="./implementation.html">Implementation</a></li>
                        <li><a href="./contribution.html">Contribution</a></li>
                        <li><a href="./safety.html">Safety</a></li>
                    </ul>
                </div>
                <div id="wetlab" class="menu_item">
                    <div class="title">Wet Lab<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./results.html">Results</a></li>
                        <li><a href="./proof.html">Proof</a></li>
                        <li><a href="./part.html">Part</a></li>
                        <li><a href="./protocol.html">Protocol</a></li>
                        <li><a href="./engineering.html">Engineering</a></li>
                        <li><a href="./measurement.html">Measurement</a></li>
                        <li><a href="./notebook.html">Notebook</a></li>
                    </ul>
                </div>
                <div id="drylab" class="menu_item">
                    <div class="title">Dry Lab<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./model.html">Model</a></li>
                        <li><a href="./software.html">Software</a></li>
                        <li><a href="./hardware.html">Hardware</a></li>
                    </ul>
                </div>
                <div id="human" class="menu_item">
                    <div class="title">Human Practice<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./hp.html">Integrated Human Practice</a></li>
                        <li><a href="./education.html">Education & Public Engagement</a></li>
                        <li><a href="./entrepreneurship.html">Entrepreneurship</a></li>
                    </ul>
                </div>
                <div id="team" class="menu_item">
                    <div class="title">Team<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./attributions.html">Attributions</a></li>
                        <li><a href="./member.html">Member</a></li>
                    </ul>
                </div>
            </div>
        </div>
        
        <!-- Banner -->
        <!-- <div class="banner">
            <img src="../static/img/logo-footer.png" alt="Description Banner">
        </div> -->
        <!-- Page Title Background -->
        <div class="page-title-bg">
            <div class="bg-image" style="background-image: url('../static/img/home/anja-bright.jpg')"></div>
            <div class="overlay"></div>
            <div class="title-content">
                <h1>Description</h1>
            </div>
        </div>

        <!-- Main content wrapper -->
        <div class="main">
            <!-- Sidebar wrapper -->
            <div class="menubg">
                <div class="sidebar">
                    <!-- sidebar collapse button -->
                    <div class="menu-collapse-btn">
                        <ion-icon name="chevron-back-outline"></ion-icon>
                    </div>
                    
                    <!-- Background -->
                    <div class="t1">
                        <a href="#background">Background</a>
                    </div>

                    <!-- Core Technology -->
                    <div class="t1">
                        <span>Core Technology</span>
                        <div class="t2">
                            <a href="#molecular-mechanisms">1. Molecular Mechanisms of Cataracts and Treatment Bottlenecks</a>
                            <a href="#innovative-solution">2. Innovative Solution: Contact Lens-Based Drug Delivery System</a>
                            <a href="#advantages">3. Advantages of Contact Lenses in Drug Delivery</a>
                            <a href="#drug-design">4. Drug Molecular Design and Optimization</a>
                            <a href="#chassis-design">5. Chassis Design and Production Method</a>
                            <a href="#biosafety-reporting">6. Biosafety Reporting Module</a>
                            <a href="#validation">7. Model Validation and Experimental Analysis</a>
                        </div>
                    </div>

                    <!-- Outlook -->
                    <div class="t1">
                        <a href="#outlook">Prospects and Application Potential</a>
                    </div>

                    <!-- References -->
                    <div class="t1">
                        <a href="#references">Reference</a>
                    </div>
                </div>
            </div>

            <!-- sidebar expand button -->
            <div class="menu-expand-btn">
                <ion-icon name="chevron-forward-outline"></ion-icon>
            </div>

            <!-- Content area -->
            <div class="content">
                <section id="background">
                    <h1>Background</h1>
                    <p>"The eye is the window to the soul." This famous quote by Leonardo da Vinci precisely highlights the critical role of vision in how humans perceive the world. However, cataracts are the most common cause of blindness globally<sup><a href="#ref1">[1]</a></sup>, affecting tens of millions of people annually, especially among middle-aged and elderly populations.</p>
                    
                    <figure>
                        <img src="../static/img/description/1.png" alt="Cataract prevalence">
                        <figcaption>
                            Figure 1: Age-standardised prevalence of blindness, moderate vision impairment, and severe vision impairment due to cataracts in 2020
                            <div class="source">
                                Source: Cicinelli MV, et al. Cataracts. Lancet. 2023<sup><a href="#ref1">[1]</a></sup>
                            </div>
                        </figcaption>
                    </figure>
                    
                    <p>Currently, the mainstream treatment for cataracts involves surgically removing the cloudy lens and implanting an artificial intraocular lens. This method demands substantial medical resources and is not widely accessible in underdeveloped regions. According to the <strong>American Academy of Ophthalmology</strong>, surgery remains the gold standard for cataract treatment<sup><a href="#ref2">[2]</a></sup>.</p>
                    
                    <p>Existing pharmacological treatments, such as eye drops, face challenges like poor drug absorption, short retention time, and the burden of frequent administration, making it difficult to achieve ideal therapeutic outcomes<sup><a href="#ref3">[3]</a></sup>. For example, antioxidants and protein aggregation reversal agents have shown some efficacy in cataract models, but due to the anatomical and physiological barriers of the eye, traditional eye drops face limited effectiveness<sup><a href="#ref4">[4]</a></sup>. Although nanotechnology has made some progress in drug delivery, further research is needed to solidify the therapeutic efficacy of these compounds and improve delivery methods<sup><a href="#ref5">[5]</a></sup>.</p>
                </section>

                <section id="core-technology">
                    <h1>Core Technology</h1>

                    <section id="molecular-mechanisms">
                        <h2>1. Molecular Mechanisms of Cataracts and Treatment Bottlenecks</h2>
                        <p>The core pathology of cataract formation is linked to the misfolding and aggregation of lens proteins, with the small heat shock protein <strong>CRYAA</strong> playing a crucial role. When its function is impaired, environmental stressors (such as low temperature and oxidative stress) or genetic mutations (like the CRYAA Y118D mutation) can cause CRYAA to lose its chaperone activity. This accelerates protein aggregation and the formation of insoluble deposits. Such protein aggregates lead to lens opacity, resulting in visual impairment or even blindness<sup><a href="#ref6">[6]</a></sup><sup><a href="#ref7">[7]</a></sup><sup><a href="#ref8">[8]</a></sup><sup><a href="#ref9">[9]</a></sup>.</p>
                        
                        <p>To break this vicious cycle, the team selected the <strong>E3 ubiquitin ligase RNF114</strong>. RNF114 precisely identifies misfolded CRYAA proteins and tags them for degradation through ubiquitination, thereby restoring lens transparency. Research has shown that RNF114 significantly reduces lens opacity in cold-induced and oxidative stress-related cataract models<sup><a href="#ref10">[10]</a></sup>. This therapeutic target offers unprecedented breakthrough potential.</p>
                    </section>

                    <section id="innovative-solution">
                        <h2>2. Innovative Solution: Contact Lens-Based Drug Delivery System</h2>
                        <p>Our team proposes a novel treatment approach: using hydrogel-based contact lenses as drug delivery carriers. Through bioengineering and modern materials science, we've designed contact lenses capable of sustained drug release. By modifying the biohydrogel system originally used for secreting hyaluronic acid to treat dry eye<sup><a href="#ref11">[11]</a></sup>, we engineered it to simultaneously secrete RNF114 for cataract treatment<sup><a href="#ref10">[10]</a></sup>.</p>
                        
                        <p>This not only enables continuous drug release but also targets the lens, fundamentally addressing the limitations of existing drug therapies. It reduces the burden of frequent drug administration for patients, aims to maintain higher average drug concentrations, and lowers systemic toxicity.</p>

                        <h3>Key Technological Modules Include:</h3>
                        <ul>
                            <li>
                                <p><strong>Biohydrogel Platform:</strong> Utilizing biohydrogel as the base material for contact lenses, we've embedded micro "biofactories" at the peripheral edges without affecting the visual field. These biofactories, engineered through synthetic biology, can continuously secrete therapeutic agents like <strong>RNF114 protein</strong> and <strong>hyaluronic acid</strong>, ensuring long-term drug delivery.</p>
                            </li>
                        </ul>

                        <figure>
                            <img src="../static/img/description/2.jpg" alt="Design and composition">
                            <figcaption>Figure 2: Design and composition of the living self-lubricating contact lens (CL). Created with BioRender.com.</figcaption>
                        </figure>

                        <figure>
                            <img src="../static/img/description/3.png" alt="Transparent hydrogel discs" style="width: 50%;">
                            <figcaption>Figure 3: Transparent PVA-VS/PVA 100:0 hydrogel discs. Scale corresponds to 1 cm.</figcaption>
                        </figure>

                        <blockquote class="quote">
                            <p>Source for Figures 2 and 3: Puertas‐Bartolomé, M., Gutiérrez‐Urrutia, I., Teruel‐Enrico, L. L., et al. (2024). Self‐Lubricating, Living Contact Lenses. <em>Advanced Materials</em>, 36(27).</p>
                            <a href="https://doi.org/10.1002/adma.202313848" class="quote-source" target="_blank">https://doi.org/10.1002/adma.202313848</a>
                        </blockquote>

                        <ul>
                            <li>
                                <p><strong>Dual Treatment for Dry Eye:</strong> The secretion of hyaluronic acid not only lubricates the eye surface, alleviating dry eye caused by prolonged contact lens wear, but also creates a stable environment for the release of other drug components. Additionally, hyaluronic acid acts as an excipient to enhance drug stability.</p>
                            </li>
                            <li>
                                <p><strong>Targeted Delivery Capability:</strong> Through molecular modifications, the drug is engineered to penetrate the cornea and target the lens specifically, ensuring both precise delivery and stability.</p>
                            </li>
                        </ul>
                    </section>

                    <section id="advantages">
                        <h2>3. Advantages of Contact Lenses in Drug Delivery</h2>
                        <p>Compared to traditional eye drops, contact lenses offer significant technological advantages:</p>
                        
                        <ul>
                            <li>
                                <p><strong>Prolonged Drug Retention Time:</strong> Approximately <strong>95% of the active substances</strong> in conventional eye drops are lost through tear drainage<sup><a href="#ref12">[12]</a></sup>. Contact lenses, however, fit closely to the eye surface, reducing drug loss due to blinking or tear flow and significantly extending drug retention time on the cornea. This design greatly improves drug bioavailability, fundamentally addressing the low absorption rates of eye drops.</p>
                            </li>
                        </ul>

                        <figure>
                            <img src="../static/img/description/4.png" alt="Drug release comparison">
                            <figcaption>Figure 4: Schematic representation of drug release time for contact lenses versus conventional topical formulations<sup><a href="#ref12">[12]</a></sup>.</figcaption>
                        </figure>

                        <ul>
                            <li>
                                <p><strong>Sustained Drug Release Mechanism:</strong> Using the selective permeability of hydrogels, the team fixed engineered bacteria to continuously produce and release active drugs. The microporous structure of the hydrogel further extends drug release duration, maintains stable drug concentrations in target tissues, and reduces the need for frequent administration.</p>
                            </li>
                        </ul>
                    </section>

                    <section id="drug-design">
                        <h2>4. Drug Molecule Design and Optimization</h2>
                        <p>We have identified a non-invasive, contact lens-based <strong>biological factory</strong> designed for the sustained release of therapeutic agents to treat cataracts. Our primary therapeutic component is <strong>RNF114</strong>, expressed using the <strong>SHuffle E. coli</strong> system as the chassis. To achieve this, we introduced an exogenous gene to enable successful RNF114 expression within SHuffle.</p>

                        <p>We obtained the human RNF114 sequence from NCBI. Since prokaryotic cells lack the splicing mechanisms found in eukaryotic cells, we aimed to extract the CDS (coding sequence) via PCR, eliminating introns to overcome the absence of post-transcriptional splicing.</p>

                        <p>However, ocular drug delivery isn't as straightforward as we imagined. The <strong>efficacy of non-invasive drug delivery systems within the eye</strong> is severely hindered by natural ocular defense barriers<sup><a href="#ref13">[13]</a></sup>—including the <strong>antimicrobial clearance mechanisms</strong> of the tear film, <strong>multiple corneal barriers</strong>, and <strong>aqueous humor dilution and drainage</strong>, all of which interfere with drug delivery. Conventional methods like <strong>liposomal encapsulation</strong> are unsuitable for continuous drug release within engineered biological systems.</p>

                        <p>To address these challenges, we employed <strong>protein modification techniques</strong> to enhance drug delivery efficiency through improvements in <strong>permeability</strong>, <strong>stability</strong>, and <strong>targeting capability</strong>.</p>
                        
                        <h3>Enhancing Permeability</h3>
                        <ul>
                            <li>
                                <p><strong>Signal Peptide for Secretion:</strong> Target proteins synthesized by engineered bacteria require guidance for successful secretion. We selected pelB as the signal peptide for directing the secretion of RNF114.</p>
                            </li>
                            
                            <li>
                                <p><strong>TAT Peptide Modification:</strong> TAT-(47–58), a cell-penetrating peptide (CPP) derived from the HIV-1 regulatory protein TAT, enhances membrane permeability through various mechanisms. It shows great potential in facilitating drug delivery into target cells<sup><a href="#ref14">[14]</a></sup>, with proven applications across multiple systems, including the eye. Studies have shown that coupling TAT peptides with RNF114 significantly improves lens clarity in cataract models. We plan to modify RNF114 with TAT peptides to boost its transmembrane transport while incorporating flexible linkers to preserve the protein's 3D structure, enabling efficient corneal penetration.</p>
                            </li>
                            
                            <li>
                                <p><strong>Endosomal Escape Mechanism (GALA Peptide):</strong> Although CPPs like TAT enhance the uptake of bioactive macromolecules via endocytosis, many internalized proteins become trapped within endosomes and are eventually degraded in lysosomes. To counteract this, we identified the GALA peptide, a synthetic amphiphilic peptide derived from mutated sequences of the HA2 protein. GALA exhibits strong membrane-disruptive properties when used in cationic liposomes and nanocarriers for drug or nucleic acid delivery. Notably, a redesigned version, GALA3, significantly improves endosomal escape efficiency for fusion proteins like BLF1<sup><a href="#ref15">[15]</a></sup>. We plan to attach GALA peptides to RNF114, enhancing endosomal escape for optimal therapeutic efficacy.</p>
                            </li>
                        </ul>

                        <h3>Improving Stability</h3>
                        <p>The RNF114 protein is prone to degradation due to the antimicrobial clearance mechanisms of ocular surface tear fluid. To address this, we first utilized the ExPASy tool to predict degradation-prone sites on the protein and attempted to enhance its stability through modifications. Initial considerations included protecting vulnerable sites via methods like PEGylation or glycosylation. However, these approaches typically rely on in vitro chemical conjugation and cannot be autonomously executed within cells, making them incompatible with our genetic circuit-based strategy. This led us to question: Is there a more adaptable optimization method?</p>
                        
                        <p>Directed evolution of proteins emerged as a potential solution, a method frequently employed in past projects (e.g., <a href="https://2022.igem.wiki/tu-dresden/description" target="_blank">TU Dresden 2022</a>). However, this path was abandoned due to the lack of a viable mechanism to link RNF114 mutations to cellular survival. Similarly, the use of protease inhibitors was rejected because of their potential interference with normal cellular activities.</p>
                        
                        <p>Ultimately, we focused on Polyol Co-Release for Protein Stabilization and Rare Amino Acid Substitution. This dual approach leverages the stabilizing effects of polyols on protein conformation while introducing steric hindrance via non-canonical amino acids to shield critical sites from enzymatic degradation.</p>

                        <h4>Polyol Co-Release for Protein Stabilization</h4>
                        <p>Polyols stabilize proteins by enhancing hydration and promoting proper folding. They form a hydration shell around the protein, acting as a protective barrier against proteolytic enzymes. This steric hindrance reduces enzyme access to cleavage sites, thereby decreasing degradation rates.</p>
                        
                        <p>Moreover, polyols prevent protein aggregation, which often exposes cleavage-prone sites, making aggregated proteins more susceptible to enzymatic degradation. Studies have shown that polyols effectively maintain proteins in their monomeric or properly folded oligomeric forms, reducing overall proteolytic degradation<sup><a href="#ref16">[16]</a></sup>.</p>
                        
                        <p>Interestingly, we discovered that the hyaluronic acid (HA) secretion module, initially designed to alleviate contact lens-induced dry eye, offers unexpected benefits. In addition to its moisturizing effects, HA serves as a promising ocular drug delivery excipient. Its high biocompatibility, biodegradability, and low immunogenicity enhance drug bioavailability. Currently available studies include drugs that utilize hyaluronic acid to act on the corpus cavernosum, conjunctiva, and anterior segment of the eye. Among which, Pilocarpine acting on the pupillary sphincter.</p>

                        <figure>
                            <img src="../static/img/description/5.png" alt="HA drug delivery mechanism">
                            <figcaption>Figure 5: Mechanism of hyaluronic acid-assisted drug delivery in ocular tissues</figcaption>
                        </figure>
                            
                        <figure>
                            <img src="../static/img/description/6.png" alt="Drug stability enhancement">
                            <figcaption>Figure 6: Enhancement of drug stability through synchronized HA release</figcaption>
                        </figure>

                        <p>We hypothesize that this drug protects its stability at the ocular surface to the aqueous humor. Thus, the stability of the drug molecule can be ensured by synchronized release of HA.</p>

                        <h4>Rare Amino Acid Substitution (Backup Strategy)</h4>
                        <p>If HA fails to sufficiently stabilize RNF114, we'll consider substituting rare amino acids. According to ExPASy predictions, arginine and lysine are the most frequently cleaved residues by ocular proteases. We plan to replace the five most vulnerable lysine residues with N-ε-Boc-lysine, using the Methanosarcina mazei PylRS variant (pCDF-Mm2) system<sup><a href="#ref17">[17]</a></sup>. The structural similarity between lysine and N-ε-Boc-lysine ensures minimal impact on RNF114's activity, while the bulky tert-butyl group provides steric hindrance against enzymatic cleavage.</p>
                        
                        <p>Due to the complexity of this approach, it will serve as a contingency plan if HA-based stabilization proves insufficient.</p>
                        
                        <figure>
                            <img src="../static/img/description/7.png" alt="backup strategy">
                        </figure>

                        <h3>Targeting Modifications</h3>
                        <p>To ensure that RNF114 reaches the lens with precision, we selected Aquaporin 0 (AQP0)—a water channel protein located on the membranes of lens fiber cells—as our targeting marker. We designed short peptides that can specifically bind to AQP0, facilitating precise drug delivery to the lens.</p>

                        <h4>Why Choose AQP0?</h4>
                        <ol>
                            <li>
                                <p><strong>High Conservation Across Species:</strong> Although the PDB database has only resolved the structure of AQP0 from sheep, this protein is highly conserved, with a 90.8% similarity between humans and sheep, making cross-species application feasible (details available in the software analysis).</p>
                            </li>
                            
                            <!-- TODO: Change this fig to chart -->
                            <!-- <figure>
                                <img src="../static/img/description/todo.png" alt="AQP0 targeting strategy">
                                <figcaption>Figure todo: AQP0 structure and targeting peptide design strategy</figcaption>
                            </figure> -->
                        
                            <div class="chart-container">
                                <div style="display: flex; gap: 20px;">
                                    <div style="flex: 1;">
                                        <canvas id="humanAQP0Chart"></canvas>
                                    </div>
                                    <div style="flex: 1;">
                                        <canvas id="sheepAQP0Chart"></canvas>
                                    </div>
                                </div>
                            <figcaption>Chart: Comparison of amino acid frequency distribution between human and sheep AQP0.</figcaption>
                            </div>

                            <figure>
                                <img src="../static/img/description/8.png" alt="AQP0 targeting strategy">
                                <figcaption>Figure 8: Sequence similarity: 90.8292%</figcaption>
                            </figure>
                            
                            <li>
                                <p><strong>Lens-Specific Expression:</strong> In mammals, AQP0 is almost exclusively expressed in lens fiber cells, accounting for approximately 50% of the membrane proteins in this tissue. Its expression in other tissues is minimal or virtually absent.</p>
                            </li>
                        </ol>
                        
                        <h4>AQP0 Overview and Design Requirements for Targeting Peptides</h4>
                        <p>AQP0 is primarily divided into two types: junctional type and non-junctional type<sup><a href="#ref18">[18]</a></sup>. The former has poor water permeability and is mainly used for intercellular junctions; the latter exhibits high water permeability and primarily maintains the osmotic balance of the lens. When the C-terminus of non-junctional AQP0 is cleaved by proteases, the bridging between the N-terminus and C-terminus breaks, leading to conformational disorder in the N-terminus and conversion to the junctional type of AQP0.</p>

                        <p>The C-terminus of AQP0 can interact with various proteins, including connexins, γE-crystallin, intermediate filaments, and Ezrin. AQP0 can also form connections with other AQP0 tetramers through extracellular loop C and loop A<sup><a href="#ref19">[19]</a></sup>.</p>

                        <p>When selecting targeting sites on AQP0, it is essential to ensure that the binding of short peptides does not interfere with its water permeability function, avoid sequences that are cleaved or altered during cleavage, avoid interaction sites with other proteins, and guarantee the specificity of the binding sites.</p>
                    
                        <h3>Protein Design</h3>

                        <h4>Selecting the Attachment Site</h4>

                        <p>Observing the dimensional structure of the drug to be modified, RNF114 (RNF114 3D structure), its possible site of action, the zinc finger, is located at amino acids 29-68 and 91-110 of the protein. We found that the N-terminal sequence of RNF114 is less folded, less confident, not a zinc finger, and less conserved, making it a suitable site for modification. Therefore, we chose to add the additional structure at the end of the N-terminus of RNF114.</p>

                        <!-- pdb file -->
                        <section id="protein-structure">
                            <div class="pdb-viewer-container">
                                <div id="viewport" data-structures='[
                                    {
                                        "path": "../static/img/description/rnf114.pdb",
                                        "color": "#7CB9E8",
                                        "name": "RNF114"
                                    },
                                    {
                                        "path": "../static/img/description/model_1_aligned.pdb",
                                        "color": "#F4C430",
                                        "name": "Model 1"
                                    }
                                ]'></div>
                                <!-- <p class="description">
                                    Three-dimensional structure of RNF114 protein. The structure shows the key binding domains and interaction sites.
                                </p> -->
                            </div>
                        </section>

                        <h4>Determining the Connection Sequence</h4>

                        <ul>
                            <li>
                                <p><strong>Signal Peptide (pelB):</strong>  Functions within engineered bacteria, guiding protein secretion.</p>
                            </li>
                            <li>
                                <p><strong>TAT Peptide:</strong> Facilitates drug penetration through the corneal barrier and entry into target cells.</p>
                            </li>
                            <li>
                                <p><strong>Targeting Peptide:</strong> Binds specifically to AQP0 on lens fiber cell membranes, ensuring accurate drug localization.</p>
                            </li>
                            <li>
                                <p><strong>GALA Peptide:</strong> Responds to pH changes, aiding in endosomal escape within target cells to ensure the drug reaches its site of action.</p>
                            </li>
                        </ul>

                        <p>Considering that pelB is cleaved during protein secretion, we positioned it at the N-terminal end of RNF114.</p>
                        <p>Since GALA peptides require conformational flexibility to function effectively, we added longer linkers to prevent structural interference with adjacent protein modules.</p>

                        <h4>Linker Selection</h4>
                        <p>We evaluated linkers of varying lengths—GS3, GS5, and GS9<sup><a href="#ref20">[20]</a></sup>—and assessed both flexible and rigid linkers respectively and we also tried to place the GALA peptide at the c-terminal end to test whether it could reduce the structural alteration of the GALA peptide on the protein. Finally, we found that the protein fusion method in the figure below had the least effect on the drug structure.</p>

                        <p>Ultimately, we identified the fusion protein configuration that preserved RNF114's structural integrity and functional activity most effectively.</p>
                    </section>

                    <section id="chassis-design">
                        <h2>5. Chassis Design and Production Method</h2>
                        <p>In order to ensure the stable expression and production of the drug, we chose the SHuffle E. coli expression system as the biofactory. It not only has enhanced oxidative folding ability and provides a standard plasmid backbone. In the future, if needed, multiple expression frameworks can be introduced to co-express auxiliary proteins required for RNF114 synthesis.</p>

                        <h3>Analysis of Key Ocular Barriers</h3>
                        <p>To optimize drug delivery efficiency, we analyzed several ocular barriers:</p>
                        <ul>
                            <li>
                                <p><strong>Tear Film Clearance Mechanism:</strong> Research indicates that 80%-90% of drugs administered via eye drops are eliminated through the nasolacrimal duct, with less than 5% reaching the intraocular tissues. By covering the cornea and integrating into the tear film, contact lenses reduce this loss significantly.</p>
                            </li>
                            <li>
                                <p><strong>Corneal Absorption Barrier:</strong> While the corneal epithelium is permeable to lipophilic drugs, hydrophilic drugs depend on paracellular transport through the stroma. Our design balances lipophilicity and hydrophilicity to improve permeability.</p>
                            </li>
                            <li>
                                <p><strong>Aqueous Humor Dynamics:</strong> By modeling drug distribution and metabolism in the anterior chamber, we ensure that RNF114 achieves effective therapeutic concentrations in the lens while avoiding rapid elimination.</p>
                            </li>
                        </ul>
                    </section>

                    <section id="biosafety-reporting">
                        <h2>6. Biosafety Reporting Module</h2>
                        <p>Engineered bacteria are encapsulated in hydrogels and depend on nutrients in the tear fluid for survival, and are affected by factors such as temperature and nutrient elements in the ocular microenvironment. In order to be able to report in time when the bacterial activity decreases and there is a risk of lysis, and to warn users to replace their contact lenses, we designed a reporter module centered on the fluorescent protein Crismcon<sup><a href="#ref21">[21]</a></sup>.</p>

                        <p>Co-expression of RNF114 and the fluorescent protein Crismcon was achieved through a multiple cis-transon structure, and the expression of RNF114 was made relatively higher by the difference in RBS intensity. After translation, the two coding genes are located on the same mRNA, and when the cellular activity decreases and the expression of RNF114 decreases, the expression of Crismcon also decreases, and a decrease in the fluorescence signal is detected to realize the safety risk report.</p>

                        <p>We fused the fluorescent signal detection device into a black contact lens care case, pressed the button, the light source excites the fluorescent protein Crismson, and the fluorescent intensity emitted by the fluorescent protein is detected by the BH1750 sensor, which determines the safety level warning according to the predetermined threshold and displays it on the LCD screen.</p>
                    </section>

                    <section id="validation">
                        <h2>7. Model Validation and Experimental Analysis</h2>
                        <p>To verify the feasibility of our design, we conducted a series of multi-level experiments:</p>

                        <ol>
                            <li>
                                <p><strong>Molecular Modeling and Structural Prediction: </strong>We used AlphaFold to predict the 3D structure of RNF114 after modification with the TAT peptide. This step ensured that RNF114 retained its biological activity post-modification and that the structural changes introduced by TAT, GALA, and other linked peptides did not disrupt its therapeutic function.</p>
                            </li>

                            <li>
                                <p><strong>Microengineered Biomimetic Ocular Models: </strong>We independently designed and constructed an in vitro eyeball simulation chip to deeply restore the physiological characteristics of tears, cornea, and aqueous reflux for evaluating the drug delivery effect of CLearCat. Compared with complicated animal experiments, this model also provides more options for the evaluation of ophthalmic drug delivery<sup><a href="#ref22">[22]</a></sup><sup><a href="#ref23">[23]</a></sup>.</p>
                            </li>
                        </ol>
                    </section>
                </section>

                <section id="outlook">
                    <h1>Prospects and Application Potential</h1>
                    <p>The CLearCat drug delivery platform not only offers a breakthrough solution for cataract treatment but also opens new avenues for managing various other ophthalmic conditions.</p>

                    <ol>
                        <li>
                            <p><strong>Expanding to Other Eye Diseases: </strong>The core of this technology is highly scalable and can be expanded for the targeted treatment of glaucoma, retinal diseases, dry eye and other ocular diseases. As these diseases often require long-term treatment and localized drug delivery, our team has proposed a new solution to address this pain point: CLearCat. Compared with existing treatment options, CLearCat's long-acting drug release feature can significantly improve efficacy and reduce the burden of frequent drug administration, bringing a better therapeutic experience to patients.</p>
                        </li>

                        <li>
                            <p><strong>Personalized Medicine Potential: </strong>The functional flexibility of CLearCat's contact lens platform makes it an ideal candidate for future integration with personalized medicine. Customizable based on individual genetic profiles or disease characteristics, CLearCat could one day provide tailor-made treatments for each patient, enhancing both efficacy and safety.</p>
                            
                            <p>This marks a transformative shift in how we perceive contact lenses—from simple vision correction tools to sophisticated therapeutic devices. Such innovations not only expand the functional scope of contact lenses but also introduce entirely new treatment options for patients worldwide.</p>
                        </li>

                        <li>
                            <p><strong>A Paradigm Shift in Ophthalmic Care: </strong>By merging modern biotechnology with materials science, CLearCat represents more than just a technical advancement—it's a potential revolution in ophthalmic medicine. This innovative platform challenges traditional treatment paradigms, offering hope to millions of patients suffering from visual impairments.</p>
                        </li>
                    </ol>

                    <blockquote class="quote" style="font-size: 1em;">
                        <p>"Medicine is a science of uncertainty and an art of probability."</p>
                        <p class="quote-source">— William Osler</p>
                    </blockquote>

                    <p>We believe that CLearCat's introduction will not only improve the quality of life for cataract patients but also bring new light and hope to millions globally.</p>
                </section>

                <section id="references">
                    <h1>Reference</h1>
                    <div class="reference-list">
                        <div class="reference-item" id="ref1">
                            <span class="ref-number">[1]</span>
                            <span class="ref-content">Cicinelli, M. V., Buchan, J. C., Nicholson, M., Varadaraj, V., & Khanna, R. C. (2023). Cataracts. <em>Lancet</em>, 401(10374), 377-389.</span>
                            <a href="https://doi.org/10.1016/S0140-6736(22)01839-6" class="ref-link" target="_blank">DOI: 10.1016/S0140-6736(22)01839-6</a>
                        </div>

                        <div class="reference-item" id="ref2">
                            <span class="ref-number">[2]</span>
                            <span class="ref-content">Miller, K. M., et al. (2022). Cataract in the Adult Eye Preferred Practice Pattern. <em>Ophthalmology</em>, 129(1), P1-P126.</span>
                            <a href="https://doi.org/10.1016/j.ophtha.2021.10.006" class="ref-link" target="_blank">DOI: 10.1016/j.ophtha.2021.10.006</a>
                        </div>

                        <div class="reference-item" id="ref3">
                            <span class="ref-number">[3]</span>
                            <span class="ref-content">Thrimawithana, T. R., et al. (2018). Drug delivery to the lens for the management of cataracts. <em>Advanced Drug Delivery Reviews</em>, 126, 185-194.</span>
                            <a href="https://doi.org/10.1016/j.addr.2018.03.009" class="ref-link" target="_blank">DOI: 10.1016/j.addr.2018.03.009</a>
                        </div>

                        <div class="reference-item" id="ref4">
                            <span class="ref-number">[4]</span>
                            <span class="ref-content">Lee, B. J., & Afshari, N. A. (2023). Advances in drug therapy and delivery for cataract treatment. <em>Current Opinion in Ophthalmology</em>, 34(1), 3-8.</span>
                            <a href="https://doi.org/10.1097/ICU.0000000000000910" class="ref-link" target="_blank">DOI: 10.1097/ICU.0000000000000910</a>
                        </div>

                        <div class="reference-item" id="ref5">
                            <span class="ref-number">[5]</span>
                            <span class="ref-content">Chen, Y., Ye, Z., Chen, H., & Li, Z. (2024). Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment. <em>International Journal of Nanomedicine</em>, 19, 4021-4040.</span>
                            <a href="https://doi.org/10.2147/IJN.S463679" class="ref-link" target="_blank">DOI: 10.2147/IJN.S463679</a>
                        </div>

                        <div class="reference-item" id="ref6">
                            <span class="ref-number">[6]</span>
                            <span class="ref-content">Puertas‐Bartolomé, M., Gutiérrez‐Urrutia, I., Teruel‐Enrico, L. L., et al. (2024). Self‐Lubricating, living contact lenses. <em>Advanced Materials</em>, 36(27).</span>
                            <a href="https://doi.org/10.1002/adma.202313848" class="ref-link" target="_blank">DOI: 10.1002/adma.202313848</a>
                        </div>

                        <div class="reference-item" id="ref7">
                            <span class="ref-number">[7]</span>
                            <span class="ref-content">Yang, H., Ping, X., Zhou, J., et al. (2024). Reversible cold-induced lens opacity in a hibernator reveals a molecular target for treating cataracts. <em>Journal of Clinical Investigation</em>, 134(18), e169666.</span>
                            <a href="https://doi.org/10.1172/JCI169666" class="ref-link" target="_blank">DOI: 10.1172/JCI169666</a>
                        </div>

                        <div class="reference-item" id="ref8">
                            <span class="ref-number">[8]</span>
                            <span class="ref-content">Moreau, K. L., & King, J. A. (2012). Protein misfolding and aggregation in cataract disease and prospects for prevention. <em>Trends in Molecular Medicine</em>, 18(5), 273-82.</span>
                            <a href="https://doi.org/10.1016/j.molmed.2012.03.005" class="ref-link" target="_blank">DOI: 10.1016/j.molmed.2012.03.005</a>
                        </div>

                        <div class="reference-item" id="ref9">
                            <span class="ref-number">[9]</span>
                            <span class="ref-content">Sprague-Piercy, M. A., Rocha, M. A., Kwok, A. O., & Martin, R. W. (2021). α-Crystallins in the Vertebrate Eye Lens: Complex Oligomers and Molecular Chaperones. <em>Annual Review of Physical Chemistry</em>, 72, 143-163.</span>
                            <a href="https://doi.org/10.1146/annurev-physchem-090419-121428" class="ref-link" target="_blank">DOI: 10.1146/annurev-physchem-090419-121428</a>
                        </div>

                        <div class="reference-item" id="ref10">
                            <span class="ref-number">[10]</span>
                            <span class="ref-content">Shiels, A., & Hejtmancik, J. F. (2021). Inherited cataracts: Genetic mechanisms and pathways new and old. <em>Experimental Eye Research</em>, 209, 108662.</span>
                            <a href="https://doi.org/10.1016/j.exer.2021.108662" class="ref-link" target="_blank">DOI: 10.1016/j.exer.2021.108662</a>
                        </div>

                        <div class="reference-item" id="ref11">
                            <span class="ref-number">[11]</span>
                            <span class="ref-content">Budnar, P., Tangirala, R., Bakthisaran, R., & Rao, C. M. (2022). Protein Aggregation and Cataract: Role of Age-Related Modifications and Mutations in α-Crystallins. <em>Biochemistry (Moscow)</em>, 87(3), 225-241.</span>
                            <a href="https://doi.org/10.1134/S000629792203004X" class="ref-link" target="_blank">DOI: 10.1134/S000629792203004X</a>
                        </div>

                        <div class="reference-item" id="ref12">
                            <span class="ref-number">[12]</span>
                            <span class="ref-content">Guo, X., Hutcheon, A. E., & Zieske, J. D. (2004). Transduction of functionally active TAT fusion proteins into cornea. <em>Exp Eye Res</em>, 78(5), 997-1005.</span>
                            <a href="https://doi.org/10.1016/j.exer.2003.12.010" class="ref-link" target="_blank">DOI: 10.1016/j.exer.2003.12.010</a>
                        </div>

                        <div class="reference-item" id="ref13">
                            <span class="ref-number">[13]</span>
                            <span class="ref-content">Rykowska, I., Nowak, I., & Nowak, R. (2021). Soft Contact Lenses as Drug Delivery Systems: A Review. <em>Molecules</em>, 26(18).</span>
                            <a href="https://doi.org/10.3390/molecules26185430" class="ref-link" target="_blank">DOI: 10.3390/molecules26185430</a>
                        </div>

                        <div class="reference-item" id="ref14">
                            <span class="ref-number">[14]</span>
                            <span class="ref-content">Wu, B., Li, M., Li, K., et al. (2021). Cell penetrating peptide TAT-functionalized liposomes for efficient ophthalmic delivery of flurbiprofen. <em>International Journal of Pharmaceutics</em>, 598, 120405.</span>
                            <a href="https://doi.org/10.1016/j.ijpharm.2021.120405" class="ref-link" target="_blank">DOI: 10.1016/j.ijpharm.2021.120405</a>
                        </div>

                        <div class="reference-item" id="ref15">
                            <span class="ref-number">[15]</span>
                            <span class="ref-content">Rizzuti, M., Nizzardo, M., Zanetta, C., Ramirez, A., & Corti, S. (2015). Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. <em>Drug Discovery Today</em>, 20(1), 76-85.</span>
                            <a href="https://doi.org/10.1016/j.drudis.2014.09.017" class="ref-link" target="_blank">DOI: 10.1016/j.drudis.2014.09.017</a>
                        </div>

                        <div class="reference-item" id="ref16">
                            <span class="ref-number">[16]</span>
                            <span class="ref-content">Li, C., Cao, X. W., Zhao, J., et al. (2020). Effective Therapeutic Drug Delivery by GALA3, an Endosomal Escape Peptide with Reduced Hydrophobicity. <em>Journal of Membrane Biology</em>, 253, 139-152.</span>
                            <a href="https://doi.org/10.1007/s00232-020-00109-2" class="ref-link" target="_blank">DOI: 10.1007/s00232-020-00109-2</a>
                        </div>

                        <div class="reference-item" id="ref17">
                            <span class="ref-number">[17]</span>
                            <span class="ref-content">Nicoud, L., Cohrs, N., Arosio, P., Norrant, E., & Morbidelli, M. (2015). Effect of polyol sugars on the stabilization of monoclonal antibodies. <em>Biophysical Chemistry</em>, 197, 40-46.</span>
                            <a href="https://doi.org/10.1016/j.bpc.2014.12.003" class="ref-link" target="_blank">DOI: 10.1016/j.bpc.2014.12.003</a>
                        </div>

                        <div class="reference-item" id="ref18">
                            <span class="ref-number">[18]</span>
                            <span class="ref-content">Lu, W., Wang, R., Wang, P., Ma, S., & Xia, Q. (2021). Genetic Code Expansion System for Tight Control of Gene Expression in Bombyx mori Cell Lines. <em>Insects</em>, 12(12), 1081.</span>
                            <a href="https://doi.org/10.3390/insects12121081" class="ref-link" target="_blank">DOI: 10.3390/insects12121081</a>
                        </div>

                        <div class="reference-item" id="ref19">
                            <span class="ref-number">[19]</span>
                            <span class="ref-content">Gonen, T., Cheng, Y., Sliz, P., et al. (2005). Lipid-protein interactions in double-layered two-dimensional AQP0 crystals. <em>Nature</em>, 438(7068), 633-638.</span>
                            <a href="https://doi.org/10.1038/nature04321" class="ref-link" target="_blank">DOI: 10.1038/nature04321</a>
                        </div>

                        <div class="reference-item" id="ref20">
                            <span class="ref-number">[20]</span>
                            <span class="ref-content">Sjöhamn, J., & Hedfalk, K. (2014). Unraveling aquaporin interaction partners. <em>Biochimica et Biophysica Acta</em>, 1840(5), 1614-1623.</span>
                            <a href="https://doi.org/10.1016/j.bbagen.2013.11.012" class="ref-link" target="_blank">DOI: 10.1016/j.bbagen.2013.11.012</a>
                        </div>

                        <div class="reference-item" id="ref21">
                            <span class="ref-number">[21]</span>
                            <span class="ref-content">Klein, J. S., Jiang, S., Galimidi, R. P., Keeffe, J. R., & Bjorkman, P. J. (2014). Design and characterization of structured protein linkers with differing flexibilities. <em>Protein Engineering, Design and Selection</em>, 27(10), 325-330.</span>
                            <a href="https://doi.org/10.1093/protein/gzu043" class="ref-link" target="_blank">DOI: 10.1093/protein/gzu043</a>
                        </div>

                        <div class="reference-item" id="ref22">
                            <span class="ref-number">[22]</span>
                            <span class="ref-content">Ning, L., Geng, Y., Lovett-Barron, M., et al. (2022). A Bright, Nontoxic, and Non-aggregating red Fluorescent Protein for Long-Term Labeling of Fine Structures in Neurons. <em>Frontiers in Cell and Developmental Biology</em>, 10, 893468.</span>
                            <a href="https://doi.org/10.3389/fcell.2022.893468" class="ref-link" target="_blank">DOI: 10.3389/fcell.2022.893468</a>
                        </div>

                        <div class="reference-item" id="ref23">
                            <span class="ref-number">[23]</span>
                            <span class="ref-content">Bennet, D., Estlack, Z., Reid, T., et al. (2018). A microengineered human corneal epithelium-on-a-chip for eye drops mass transport evaluation. <em>Lab on a Chip</em>, 18(11), 1539-1551.</span>
                            <a href="https://doi.org/10.1039/C8LC00158H" class="ref-link" target="_blank">DOI: 10.1039/C8LC00158H</a>
                        </div>
                    </div>
                </section>
            </div>
        </div>

        <!-- Footer -->
        <footer id="footer">
            <div class="logo_wrap">
                <img id="team_logo" src="../static/img/Logo-round-text.svg" alt="">
            </div>
            <div class="follow">
                <div class="title">Follow Us</div>
                <ul class="follow_list">
                    <li><a href="https://space.bilibili.com/700401359?spm_id_from=333.337.search-card.all.click" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-bilibili.png" alt=""></a></li>
                    <li><a href="https://twitter.com/ZjuChina" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-twitter.png" alt=""></a></li>
                    <li><a href="https://mp.weixin.qq.com/s/yTMIiH4AQ2skqP-7cXr7Ig" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-wechat.png" alt=""></a></li>
                </ul>
            </div>
            <div class="contact">
                <div class="title">Contact Us</div>
                <div class="email">ZJU_China@outlook.com</div>
            </div>
        </footer>
        <script src="../static/js/basic.js"></script>
        <script src="../static/js/pages.js"></script>
        <script src="../static/js/pdbviewer.js"></script>
        <script src="../static/js/components.js"></script>
    </body>
</html>